Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study

被引：0
|
作者：
Ching-Liang Ho
Tsu-Yi Chao
Chia-Lun Chang
Hsuan-Yu Lin
机构：
[1] Tri-Service General Hospital,Division of Hematology and Oncology
[2] National Defense Medical Center,Division of Hematology and Oncology
[3] Taipei Tzu Chi Hospital,Division of Hematology and Oncology
[4] Buddhist Tzu Chi Medical Foundation,Division of Hematology and Oncology
[5] Taipei Medical University-Shuang Ho Hospital,Division of Hematology and Oncology, Department of Internal Medicine
[6] Ministry of Health and Welfare,undefined
[7] Taipei Municipal Wanfang Hospital,undefined
[8] Changhua Christian Hospital,undefined
来源：
BioDrugs | 2024年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：287 / 299
页数：12
相关论文
共 50 条
  • [31] Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study
    Teran Brage, E.
    Vidal Tocino, R.
    Moreno Gomez, A.
    Figuero Perez, L.
    Lopez Gutierrez, A.
    Lozano Mejorada, R.
    Fonseca Sanchez, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S325 - S325
  • [32] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [33] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [34] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Day, Daphne
    Park, John J.
    Coward, Jermaine
    Markman, Ben
    Lemech, Charlotte
    Kuo, James C.
    Prawira, Amy
    Brown, Michael P.
    Bishnoi, Sarwan
    Kotasek, Dusan
    Strother, R. Matthew
    Cosman, Rasha
    Su, Rila
    Ma, Yiding
    Yue, Zenglian
    Hu, Hui-han
    Wu, Rachel
    Li, Peiqi
    Tse, Archie N.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1608 - 1618
  • [35] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Daphne Day
    John J. Park
    Jermaine Coward
    Ben Markman
    Charlotte Lemech
    James C. Kuo
    Amy Prawira
    Michael P. Brown
    Sarwan Bishnoi
    Dusan Kotasek
    R. Matthew Strother
    Rasha Cosman
    Rila Su
    Yiding Ma
    Zenglian Yue
    Hui-han Hu
    Rachel Wu
    Peiqi Li
    Archie N. Tse
    British Journal of Cancer, 2023, 129 : 1608 - 1618
  • [36] Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study.
    Huang, Jing
    Zhang, Bo
    Wang, Ying
    Wang, Feng
    Wu, Shikai
    Zheng, Yi
    Xu, Jianping
    Lan, Dongmei
    Wei, Min
    Liu, Sijun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors
    Callahan, Margaret K.
    Ott, Patrick Alexander
    Odunsi, Kunle
    Bertolini, Staphane V.
    Pan, Linda S.
    Venhaus, Ralph Rudolph
    Karakunnel, Joyson Joseph
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial
    Du, Yiqun
    Zhang, Jian
    Sun, Meili
    Wen, Qing
    Zheng, Yawen
    Tolcher, Anthony W.
    Sommerhalder, David
    Wang, Zhen
    Li, Xiumin
    Gao, Zhenyuan
    Zhou, Huan
    Liu, Lian
    Wang, Benjie
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Li, Chao
    Li, Jiangfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Anti-PD-1 for patients with leptomeningeal metastasis from advanced solid tumors: Efficacy, safety, and biomarkers of response.
    Naidoo, Jarushka
    Schreck, Karisa C.
    Hu, Chen
    Douville, Christopher Blair
    Santa-Maria, Cesar Augusto
    Connolly, Roisin M.
    Holdhoff, Matthias
    Lipson, Evan J.
    Parkinson, Rose
    Riemer, Joanne
    Barnes, Amanda
    Venkatesan, Arun
    Bettegowda, Chetan
    Grossman, Stuart A.
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
    Di Giacomo, A. M.
    Schenker, M.
    Medioni, J.
    Mandziuk, S.
    Majem, M.
    Gravis, G.
    Cornfeld, M.
    Ranganathan, S.
    Lou, S.
    Csoszi, T.
    ESMO OPEN, 2024, 9 (03)
12345